噻托溴铵奥达特罗能倍乐的适应症

Bronchitis is a common respiratory disease. Typical symptoms are that patients will have coughing and other symptoms. Some patients are accompanied by sputum, etc. It is recommended that timely treatment be carried out. In daily life, people should pay attention to drinking more warm water and eating more light food. So what are the indications?

Tiotropium Bromide Odaterol Respimat Indications: Sihehua Respimat is suitable for long-term maintenance treatment of patients with chronic obstructive pulmonary disease (COPD, referred to as COPD, including chronic bronchitis and emphysema) to relieve symptoms.

Tiotropium bromide, olodaterol and Respimat are administered through the original soft mist inhalation device Respimat, which can actively spray and make it easy for patients to inhale. At the same time, it can deliver the drug stably and ensure efficient lung deposition, which is conducive to ensuring the efficacy of the drug.

Currently, tiotropium bromide, olodaterol and Respimat have been approved for marketing in my country. In this regard, Feng Nide, head of Boehringer Ingelheim's human pharmaceuticals business in Greater China, said: "Boehringer Ingelheim has been working in the field of respiratory diseases for more than 90 years, especially in the field of COPD, and has developed and launched a number of excellent products. We We are pleased to bring tiotropium bromide and olodaterol Respimat to Chinese COPD patients and doctors. At the same time, we are committed to working with experts and doctors in the respiratory field to contribute to improving the diagnosis and treatment of COPD in China and benefiting Chinese COPD patients.”

In a research trial, 298 patients with chronic obstructive pulmonary disease were included and randomly divided into an observation group (149 cases) and a control group (149 cases). The observation group was treated with tiotropium bromide, olodaterol, and repimat for 3 months, and the control group was treated with aminophylline for 3 months. The results showed that the lung function increase index of patients treated with tiotropium bromide, olodaterol, and repimat was significantly better than that of the control group, and the difference was statistically significant. In terms of the incidence of adverse reactions, the incidence rate in the tiotropium bromide olodaterol and repimat treatment group was 3.3%, and that in the control group was 10.7%. The difference between the two groups was statistically significant. Treatment of patients with tiotropium bromide, olodaterol, and repimat can effectively improve lung function indicators with significant results.

Patients must use it under the doctor's advice, pay attention to the side effects of the drug, and take countermeasures.

Recommended related hot articles: /newsDetail/83869.html